We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellix Launches Semi-Automated, High Throughput Cell-Adhesion Assay Platform
Product News

Cellix Launches Semi-Automated, High Throughput Cell-Adhesion Assay Platform

Cellix Launches Semi-Automated, High Throughput Cell-Adhesion Assay Platform
Product News

Cellix Launches Semi-Automated, High Throughput Cell-Adhesion Assay Platform


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellix Launches Semi-Automated, High Throughput Cell-Adhesion Assay Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellix Ltd. has announced that its worldwide launch of its VenaFlux™ Platform. The VenaFlux™, the first semi-automated, high throughput microfluidic cell- based assay system, measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow.

The system thereby is designed to offer scientists an important and tool for drug discovery. The VenaFlux™ is simple to use, reduces layers of animal model studies, and delivers specific and reproducible results, the company claims.

Using the VenaFlux™, scientists can obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states.

"Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies," said Vivienne Williams, CEO of Cellix Ltd. "Our VenaFlux™ accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.

Cellix's technology can provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. "To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterize drug effects," commented Ms. Williams.

Advertisement